# Franklin Berger

> Franklin Berger is a seed investor at J.P. Morgan Securities Inc. backing Health Care. See 8 investments, round sizes, portfolio and contact details. Updated…

- Type: Angel Investor
- Fund: [J.P. Morgan Securities Inc.](https://shizune.co/investors/profile/j-p-morgan-securities-inc)
- Location: New York, United States
- Total investments: 8
- Last investment: Feb 2025
- Lead investor: 0%
- Last updated: Oct 2026
- LinkedIn: https://www.linkedin.com/in/franklinberger01

Franklin Berger is a seed investor at J.P. Morgan Securities Inc. in New York focused on Health Care and Therapeutics. Franklin Berger has served as a member of our board of directors since September 2010. Franklin Berger is a consultant to biotechnology industry participants, including major biopharmaceutical firms, mid-capitalization biotechnology companies, specialist asset managers and venture capital companies, providing business development, strategicadvisory, financing, partnering, and royalty acquisition advice. Franklin Berger is also a biotechnology industry analyst with over 25 years of experience in capital markets and financial analysis. Franklin Berger worked at Sectoral Asset Management as a founder of the small-cap focused NEMO Fund from 2007 through June 2008.From May 1998 to March 2003, he served at J.P. Morgan Securities, most recently as Managing Director, Equity Research and Senior Biotechnology Analyst. In this position, he initiated coverage of 26 biotechnology companies and was responsible for technical, scientific and clinical due diligence as well as company selection.Franklin began his career as a sell-side analyst at Josephthal & Co. in 1991, subsequently moving to Salomon Smith Barney in 1997 serving as Director, Equity Research and Senior Biotechnology Analyst. Franklin currently serves on the board of directors of three biotechnology companies: Five Prime Therapeutics, Inc., Immune Design Corp. and Bellus Health, Inc. Previous public company board service included 11 years with Seattle Genetics, Inc., 7 years with VaxGen, Inc. and Aurinia Pharmaceuticals Inc. (previously Isotechnika Pharma Inc.), based in Canada. He also serves or has served on biotech company boards of directors including iTherX Pharma, Inc., Caprion Proteomics Inc. and ViroChem Pharma, Inc. (purchased by Vertex Pharmaceuticals, Inc. for $400 million in 2009). Franklin has led multiple M&A analyses resulting in greater than $1 billion in transaction value.. Franklin received a B.A. in International Relations and an M.A. in International Economics both from Johns Hopkins University and an M.B.A. from the Harvard Business School.

## Contacts

5 contacts available for Franklin Berger: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/franklin-m-berger?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 50% |
| Therapeutics | 4 | 50% |
| Biotechnology | 4 | 50% |
| Medical | 2 | 25% |
| Wellness | 1 | 13% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 25% |
| Series A | 2 | 25% |
| Series B | 2 | 25% |
| Series C | 1 | 13% |
| Funding Round | 1 | 13% |

## Investments

| Company | Description | Round size | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Auron Therapeutics | Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancerto normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. | $27.3M | Series B | Feb 04, 2025 | https://aurontx.com/ |
| Auron Therapeutics | Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancerto normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. | $48M | Series A | Jul 20, 2022 | https://aurontx.com/ |
| MindRhythm | MindRhythm is a medical device company focused on applying novel biometrics to stroke and concussion patients to improve diagnosis, triage and management. Their proprietary monitoring devices and communication platform provide novel and real-time visibility to life-threatening situations prehospital and in the operating room, allowing clinicians tointervene earlier and with better precision to prevent brain damage. | $5M | Seed | Aug 24, 2021 | https://mindrhythm.com |
| Auron Therapeutics | Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancerto normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. | $12.8M | Seed | Jan 28, 2021 | https://aurontx.com/ |
| Amphivena Therapeutics | Amphivena Therapeutics is a clinical-stage immuno-oncology company that develops a platform of dual-function biologics. Its Amphivena ReSTORE platform provides dual-action biologics that relieve immune suppression and activate T cell effector function in cancer patients. The platform design integrates elements of avidity, target selectivity, andenhanced safety within a single molecule. It is also can be engineered with additional solid tumor targeting modalities to add functionality such as directed tumor cell killing.It was founded in 2012 and is headquartered in South San Francisco, California. | $62M | Series C | Sep 24, 2019 | https://amphivena.com/ |
| Applied Therapeutics | Applied Therapeutics operates as a biotechnology company. The company focuses on developing transformative drugs in areas of high unmet medical need -fatal and debilitating diseases for which no therapies are approved. The company is developing a pipeline of novel product candidates against previously validated and well-known molecular targets. Ituses technological advances and abbreviated regulatory pathways, wherever possible, to design drugs for indications of significant unmet medical needs. | $25M | Series B | Feb 01, 2019 | http://www.appliedtherapeutics.com/ |
| Applied Therapeutics | Applied Therapeutics operates as a biotechnology company. The company focuses on developing transformative drugs in areas of high unmet medical need -fatal and debilitating diseases for which no therapies are approved. The company is developing a pipeline of novel product candidates against previously validated and well-known molecular targets. Ituses technological advances and abbreviated regulatory pathways, wherever possible, to design drugs for indications of significant unmet medical needs. | $6.1M | Series A | Feb 08, 2017 | http://www.appliedtherapeutics.com/ |
| Five Prime Therapeutics | FivePrime is dis­cov­er­ing and devel­op­ing novel ther­a­peu­tic pro­teins and anti­bod­ies by sys­tem­at­i­cally screen­ing all rel­e­vant pro­teins in the human body to find the best pro­tein for treat­ment of a given clin­i­cal indi­ca­tion. FivePrime’s Pro­Screen Engine enables the rapid pro­duc­tion and screen­ing of all ther­a­peu­ti­callyrel­e­vant pro­teins in medically-​​focused assays at the high­est qual­ity stan­dards in the indus­try. This pow­er­ful approach is the polar oppo­site of the industry’s tra­di­tional “one pro­tein at a time”. The Pro­Screen Engine com­prises the defin­i­tive pro­tein col­lec­tion and screen­ing process for bio­log­ics dis­cov­ery and is unprece­dented in its effi­ciency, qual­ity, and scale. In addi­tion to DBL Investors, investors include Domain Asso­ciates, Ver­sant Ven­tures, Kleiner Perkins Cau­field and Byers, Texas Pacific Group, Health­Cap, and Advanced Tech­nol­ogy Ventures. | $45M |  | Feb 08, 2005 | http://www.fiveprime.com |

8 of 8 investments shown.

## Co-investors
- [Polaris Partners](https://shizune.co/investors/profile/polaris-partners) — VC Fund, 4 deals together
- [Qiming Venture Partners USA](https://shizune.co/investors/profile/qiming-venture-partners-usa) — VC Fund, 4 deals together
- [Arkin Bio Ventures](https://shizune.co/investors/profile/arkin-bio-ventures) — VC Fund, 3 deals together
- [BrightEdge Fund](https://shizune.co/investors/profile/brightedge-fund) — VC Fund, 3 deals together
- [Casdin Capital](https://shizune.co/investors/profile/casdin-capital) — VC Fund, 3 deals together
- [Eli Lilly](https://shizune.co/investors/profile/eli-lilly) — VC Fund, 3 deals together

## About J.P. Morgan Securities Inc.

VC Fund · New York, United States

J.P. Morgan is a global industry leader with more than $13.7 trillion in assets under custody and $5.1 trillion in assets under administration. They provide innovative custody, fund accounting and administration and securities services to the world's largest institutional investors, alternative asset managers and debt and equity issuers.They leverage scale and capabilities in more than 90 markets to help clients optimize efficiency, mitigate risk and enhance revenue through a broad range of investor services as well as securities clearance, collateral management and alternative investment services.As a strategic partner with a long-standing commitment and proven experience, J.P. Morgan takes a consultative approach to working with clients to assess and address their individual needs. J.P. Morgan is a leader in asset management, investment banking, private banking, treasury and securities services, and commercial banking. Today, the firm serves one of the largest client franchises in the world, including corporations, institutional investors, hedge funds, governments and affluent individuals in more than 100 countries.J.P. Morgan's core businesses include:Asset Management Investment BankPrivate BankingSecurities ServicesTreasury ServicesCommercial Banking

5 contacts available at J.P. Morgan Securities Inc..

| Name | Title | Profile |
| --- | --- | --- |
| Douglas Anmuth | Managing Director, Internet Analyst | https://shizune.co/investors/profile/douglas-anmuth |
| Efstathios N Karanikolaidis | Managing Director | https://shizune.co/investors/profile/efstathios-n-karanikolaidis |
| Fernando Okumura | Team Member | https://shizune.co/investors/profile/fernando-okumura |
| Imran Khan | Managing Director | https://shizune.co/investors/profile/imran-khan |
| Imran Khan | Managing Director | https://shizune.co/investors/profile/imram-khan |

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund

### Similar country
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [SV Angel](https://shizune.co/investors/profile/sv-angel) — VC Fund

## Featured in investor lists
- [Biotech Angel Investors in United States](https://shizune.co/investors/biotech-angel-investors-united-states)

## FAQ

### What does Franklin Berger invest in?

Franklin Berger invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Seed and Series A stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Franklin Berger?

Public channels for Franklin Berger include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Franklin Berger last invest?

The most recent investment recorded for Franklin Berger closed in Feb 2025. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co